van Dyk M - Search Results

1

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

Rowland A, van Dyk M, Mangoni AA, Miners JO, McKinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ. Rowland A, et al. Among authors: van dyk m. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):31-49. doi: 10.1080/17425255.2016.1229303. Epub 2016 Sep 1. Expert Opin Drug Metab Toxicol. 2017. PMID: 27561659 Review.

2

Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease.

van Dyk M, Mangoni AA, McEvoy M, Attia JR, Sorich MJ, Rowland A. van Dyk M, et al. Clin Chim Acta. 2015 Jul 20;447:59-65. doi: 10.1016/j.cca.2015.05.014. Epub 2015 May 28. Clin Chim Acta. 2015. PMID: 26026257

3

A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing.

van Dyk M, Miners JO, Kichenadasse G, McKinnon RA, Rowland A. van Dyk M, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:17-26. doi: 10.1016/j.jchromb.2016.07.046. Epub 2016 Jul 26. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 27521531

4

Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Rowland A, van Dyk M, Warncken D, Mangoni AA, Sorich MJ, Rowland A. Rowland A, et al. Among authors: van dyk m. Br J Clin Pharmacol. 2018 Mar;84(3):501-509. doi: 10.1111/bcp.13478. Epub 2018 Jan 10. Br J Clin Pharmacol. 2018. PMID: 29178272 Free PMC article. Clinical Trial.

5

Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.

van Dyk M, Marshall JC, Sorich MJ, Wood LS, Rowland A. van Dyk M, et al. Eur J Clin Pharmacol. 2018 Jul;74(7):913-920. doi: 10.1007/s00228-018-2450-4. Epub 2018 Mar 23. Eur J Clin Pharmacol. 2018. PMID: 29572563 Clinical Trial.

6

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ. Rowland A, et al. Among authors: van dyk m. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19. Clin Pharmacol Ther. 2018. PMID: 29574693

7

Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.

Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood LS, Meech R, Mackenzie PI, Rodrigues AD, Marshall JC, Sorich MJ. Rowland A, et al. Among authors: van dyk m. Br J Clin Pharmacol. 2019 Jan;85(1):216-226. doi: 10.1111/bcp.13793. Epub 2018 Nov 16. Br J Clin Pharmacol. 2019. PMID: 30340248 Free PMC article.

8

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.

Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A. Sorich MJ, et al. Among authors: van dyk m. J Clin Pharmacol. 2019 Jun;59(6):872-879. doi: 10.1002/jcph.1377. Epub 2019 Jan 11. J Clin Pharmacol. 2019. PMID: 30633368

9

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.

Hopkins AM, Van Dyk M, Rowland A, Sorich MJ. Hopkins AM, et al. Among authors: van dyk m. Pigment Cell Melanoma Res. 2019 Jul;32(4):576-583. doi: 10.1111/pcmr.12773. Epub 2019 Feb 28. Pigment Cell Melanoma Res. 2019. PMID: 30758912

10

Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.

van Dyk M, Miners JO, Marshall JC, Wood LS, Hopkins A, Sorich MJ, Rowland A. van Dyk M, et al. Eur J Clin Pharmacol. 2019 Sep;75(9):1211-1218. doi: 10.1007/s00228-019-02682-5. Epub 2019 May 23. Eur J Clin Pharmacol. 2019. PMID: 31123759 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page